DelveInsight’s, “AL Amyloidosis Pipeline Insight 2023,” report provides comprehensive insights about 10+ companies and 10+ pipeline drugs in the AL Amyloidosis pipeline landscape. It covers the AL Amyloidosis pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

 

Key Takeaways from the AL Amyloidosis Pipeline Report

• DelveInsight’s AL Amyloidosis pipeline report depicts a robust space with 10+ active players working to develop 10+ pipeline therapies for AL Amyloidosis treatment.
• The leading companies working in the AL Amyloidosis Market include Caelum Biosciences, Nexcella Inc., HaemaLogiX Ltd., Prothena, Zentalis Pharmaceuticals, Sorrento Therapeutics Inc., and others.
• Promising AL Amyloidosis Pipeline Therapies in the various stages of development include CAEL-101, Daratumumab, Ixazomib, Cyclophosphamide, Dexamethasone, Belantamab mafodotin, Bendamustine, and others.
• In February 2023, Life Molecular Imaging GmbH announced a study of Phase 3 Clinical Trials for [18F]florbetaben. This is an open-label, multi-center pivotal Phase 3 study to visually and quantitatively assess PET images obtained after single application of 300 MBq [18F]florbetaben and PET scanning of patients with suspected cardiac amyloidosis.
• In August 2023, Alexion announced a study of Phase 3 Clinical Trials for CAEL-101 and cyclophosphamide, bortezomib, and dexamethasone (CyBorD) regimen. The primary purpose of this study is to determine whether CAEL-101, a monoclonal antibody that removes AL amyloid deposits from tissues and organs, improves overall survival and it is safe and well tolerated in patients with stage IIIa AL amyloidosis.

 

Request a sample and discover the recent advances in AL Amyloidosis Treatment Drugs @ AL Amyloidosis Pipeline Report

 

The AL Amyloidosis pipeline report provides detailed profiles of pipeline assets, a comparative analysis of clinical and non-clinical stage AL Amyloidosis drugs, inactive and dormant assets, a comprehensive assessment of driving and restraining factors, and an assessment of opportunities and risks in the AL Amyloidosis clinical trial landscape.

 

AL Amyloidosis Overview

AL Amyloidosis is the most common type, with approximately 4,500 new cases diagnosed every year. It usually affects people from ages 50-80, although there are a few cases of people being diagnosed as early as their late 20s. About two-thirds of the patients are male.

 

Find out more about AL Amyloidosis Treatment Drugs @ Drugs for AL Amyloidosis Treatment

 

AL Amyloidosis Emerging Drugs Profile

• CAEL-101: Caelum Biosciences
• NXC-201: Nexcella, Inc.

 

AL Amyloidosis Pipeline Therapeutics Assessment

There are approx. 10+ key companies which are developing the therapies for AL Amyloidosis. The AL Amyloidosis companies which have their AL Amyloidosis drug candidates in the most advanced stage, i.e. phase III.

 

Learn more about the emerging AL Amyloidosis Pipeline Therapies @ AL Amyloidosis Clinical Trials Assessment

 

Scope of the AL Amyloidosis Pipeline Report

• Coverage- Global
• Encephalopathy Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
• Encephalopathy Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
• AL Amyloidosis Companies- Caelum Biosciences, Nexcella Inc., HaemaLogiX Ltd., Prothena, Zentalis Pharmaceuticals, Sorrento Therapeutics Inc., and others.
• AL Amyloidosis Pipeline Therapies- CAEL-101, Daratumumab, Ixazomib, Cyclophosphamide, Dexamethasone, Belantamab mafodotin, Bendamustine, and others.

 

Dive deep into rich insights for new drugs for AL Amyloidosis Treatment, Visit @ AL Amyloidosis Market Drivers and Barriers, and Future Perspective

 

Table of Content

1. Introduction
2. AL Amyloidosis Executive Summary
3. AL Amyloidosis Overview
4. AL Amyloidosis Pipeline Therapeutics
5. AL Amyloidosis Therapeutic Assessment
6. AL Amyloidosis– DelveInsight’s Analytical Perspective
7. Late Stage Products (Phase III)
8. CAEL-101: Caelum Biosciences
9. Drug profiles in the detailed report…..
10. Mid Stage Products (Phase II)
11. Drug Name: Company Name
12. Drug profiles in the detailed report…..
13. Early Stage Products (Phase I)
14. NXC-201: Nexcella, Inc.
15. Drug profiles in the detailed report…..
16. Preclinical and Discovery Stage Products
17. LambdaMab 10B3 & 7F11: HaemaLogiX Ltd.
18. Drug profiles in the detailed report…..
19. Inactive Products
20. AL Amyloidosis Key Companies
21. AL Amyloidosis Key Products
22. AL Amyloidosis- Unmet Needs
23. AL Amyloidosis- Market Drivers and Barriers
24. AL Amyloidosis- Future Perspectives and Conclusion
25. AL Amyloidosis Analyst Views
26. AL Amyloidosis Key Companies
27. Appendix

 

For further information on the AL Amyloidosis Pipeline therapeutics, reach out to AL Amyloidosis Unmet Needs and Analyst Views

 

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/consulting